Cargando…
Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage
The E484K mutation at the SARS-CoV-2 Spike protein emerged independently in different variants around the world and has been widely associated with immune escape from neutralizing antibodies generated during previous infection or vaccination. In this work, the B.1 + L249S+E484K lineage was isolated...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585963/ https://www.ncbi.nlm.nih.gov/pubmed/34780883 http://dx.doi.org/10.1016/j.virusres.2021.198629 |
_version_ | 1784597797252628480 |
---|---|
author | Álvarez-Díaz, Diego A. Laiton-Donato, Katherine Torres-García, Orlando Alfredo Ruiz-Moreno, Hector Alejandro Franco-Muñoz, Carlos Beltran, Maria Angie Mercado-Reyes, Marcela Rueda, Miguel Germán Muñoz, Ana Luisa |
author_facet | Álvarez-Díaz, Diego A. Laiton-Donato, Katherine Torres-García, Orlando Alfredo Ruiz-Moreno, Hector Alejandro Franco-Muñoz, Carlos Beltran, Maria Angie Mercado-Reyes, Marcela Rueda, Miguel Germán Muñoz, Ana Luisa |
author_sort | Álvarez-Díaz, Diego A. |
collection | PubMed |
description | The E484K mutation at the SARS-CoV-2 Spike protein emerged independently in different variants around the world and has been widely associated with immune escape from neutralizing antibodies generated during previous infection or vaccination. In this work, the B.1 + L249S+E484K lineage was isolated along with A.1, B.1.420, and B.1.111 SARS-CoV-2 lineages without the E484K mutation and the neutralizing titer of convalescent sera was compared using microneutralization assays. While no significant differences in the neutralizing antibody titers were found between A.1 and B.lineages without the E484K mutation, the neutralizing titers against B.1 + L249S+E484K were 1.5, 1.9, 2.1, and 1.3-fold lower than against A.1, B.1.420, B.1.111-I, and B.1.111-II, respectively. However, molecular epidemiological data indicate that there is no increase in the transmissibility rate associated with this new lineage. This study supports the capability of new variants with the E484K mutation to be resistant to neutralization by humoral immunity, and therefore the need to intensify surveillance programs to determine if these lineages represent a risk for public health. |
format | Online Article Text |
id | pubmed-8585963 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85859632021-11-12 Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage Álvarez-Díaz, Diego A. Laiton-Donato, Katherine Torres-García, Orlando Alfredo Ruiz-Moreno, Hector Alejandro Franco-Muñoz, Carlos Beltran, Maria Angie Mercado-Reyes, Marcela Rueda, Miguel Germán Muñoz, Ana Luisa Virus Res Article The E484K mutation at the SARS-CoV-2 Spike protein emerged independently in different variants around the world and has been widely associated with immune escape from neutralizing antibodies generated during previous infection or vaccination. In this work, the B.1 + L249S+E484K lineage was isolated along with A.1, B.1.420, and B.1.111 SARS-CoV-2 lineages without the E484K mutation and the neutralizing titer of convalescent sera was compared using microneutralization assays. While no significant differences in the neutralizing antibody titers were found between A.1 and B.lineages without the E484K mutation, the neutralizing titers against B.1 + L249S+E484K were 1.5, 1.9, 2.1, and 1.3-fold lower than against A.1, B.1.420, B.1.111-I, and B.1.111-II, respectively. However, molecular epidemiological data indicate that there is no increase in the transmissibility rate associated with this new lineage. This study supports the capability of new variants with the E484K mutation to be resistant to neutralization by humoral immunity, and therefore the need to intensify surveillance programs to determine if these lineages represent a risk for public health. Published by Elsevier B.V. 2022-01-15 2021-11-12 /pmc/articles/PMC8585963/ /pubmed/34780883 http://dx.doi.org/10.1016/j.virusres.2021.198629 Text en © 2021 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Álvarez-Díaz, Diego A. Laiton-Donato, Katherine Torres-García, Orlando Alfredo Ruiz-Moreno, Hector Alejandro Franco-Muñoz, Carlos Beltran, Maria Angie Mercado-Reyes, Marcela Rueda, Miguel Germán Muñoz, Ana Luisa Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage |
title | Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage |
title_full | Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage |
title_fullStr | Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage |
title_full_unstemmed | Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage |
title_short | Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage |
title_sort | reduced levels of convalescent neutralizing antibodies against sars-cov-2 b.1+l249s+e484k lineage |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585963/ https://www.ncbi.nlm.nih.gov/pubmed/34780883 http://dx.doi.org/10.1016/j.virusres.2021.198629 |
work_keys_str_mv | AT alvarezdiazdiegoa reducedlevelsofconvalescentneutralizingantibodiesagainstsarscov2b1l249se484klineage AT laitondonatokatherine reducedlevelsofconvalescentneutralizingantibodiesagainstsarscov2b1l249se484klineage AT torresgarciaorlandoalfredo reducedlevelsofconvalescentneutralizingantibodiesagainstsarscov2b1l249se484klineage AT ruizmorenohectoralejandro reducedlevelsofconvalescentneutralizingantibodiesagainstsarscov2b1l249se484klineage AT francomunozcarlos reducedlevelsofconvalescentneutralizingantibodiesagainstsarscov2b1l249se484klineage AT beltranmariaangie reducedlevelsofconvalescentneutralizingantibodiesagainstsarscov2b1l249se484klineage AT mercadoreyesmarcela reducedlevelsofconvalescentneutralizingantibodiesagainstsarscov2b1l249se484klineage AT ruedamiguelgerman reducedlevelsofconvalescentneutralizingantibodiesagainstsarscov2b1l249se484klineage AT munozanaluisa reducedlevelsofconvalescentneutralizingantibodiesagainstsarscov2b1l249se484klineage |